

Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTION)

 consortiapedia.fastercures.org/consortia/action/

Research Areas



Tool Development

Clinical Trial



Data-Sharing Enabler



Product Development

At a Glance

- Status: **Active Consortium**
- Year Launched: **2010**
- Initiating Organization: **University of Rochester**
- Initiator Type: **Academia**
- Location: **North America**

Abstract

Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTION) is a multi-phase consortium that was formed in response to the U.S. Food and Drug Administration's (FDA) Critical Path Initiative. The purpose of this public-private partnership is to streamline the discovery and development processes for new analgesic, anesthetic, and addiction medications. Key activities involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders—including, but not limited to, academia, FDA, and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations—with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

Mission

ACTION serves as a public-private partnership with the FDA. Its purpose is to identify, prioritize,



sponsor, coordinate, and promote innovative activities—with a special interest in optimizing clinical trials—that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health. Key activities involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders—including, but not limited to, academia, FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations—with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

Multiple consortia operate under the ACTTION umbrella, including:

Consortium History

2011: University of Rochester sponsors the Accelerating the Development of Enhanced Pain Treatments meeting in Bermuda.

2011: Inaugural Scientific Workshop is held at the FDA White Oak Campus in Maryland.

2012: Second scientific workshop is held.

2014: Third scientific workshop is held.

Structure & Governance

The academic founders (Robert H. Dworkin, PhD, University of Rochester; Dennis C. Turk, PhD, University of Washington) serve as the chair and vice-chair of the Executive Committee.

Financing

Industry participants pay a membership fee to support the management and operations of the consortium; the University of Rochester serves as a custodian of the funds. The University of Rochester relies on a quarterly budget review by the ACTTION Steering Committee as the authorization for all payments from the ACTTION industry account.



Impact/Accomplishment

As of May 2014, six ACTTION articles had been published or accepted since January 2014.

Links/Social Media Feed

Homepage

<http://www.action.org/home>

Points of Contact

Robert H. Dworkin, PhD, ACTTION Director

Professor of Anesthesiology, Neurology, Oncology, and Psychiatry

Professor of Neurology in the Center for Human Experimental Therapeutics

University of Rochester School of Medicine and Dentistry

601 Elmwood Avenue, Box 604

Rochester, NY 14642

phone: (585) 275-8214

fax: (585) 276-0122

email: robert_dworkin@urmc.rochester.edu

Dennis C. Turk, PhD, ACTTION Associate Director

John and Emma Bonica Professor of Anesthesiology & Pain Research

Director, Center for Pain Research on Impact, Measurement, & Effectiveness (C-PRIME)

Editor-in-Chief, Clinical Journal of Pain

Department of Anesthesiology & Pain Medicine, Box 356540

University of Washington

Seattle, WA 98195

phone: (206) 616-2626

fax: (206) 543-2958

email: turkdc@uw.edu



Sponsors & Partners

[American Academy of Neurology](#)
[American Academy of Pain Medicine](#)
[American Chronic Pain Association](#)
[American College of Rheumatology](#)
[American Pain Society](#)
[American Society of Anesthesiologists](#)
[ANNOVATION](#)
[Astellas](#)
[Chronic Pain Research Alliance](#)
[Coleggium Pharmaceutical](#)
[Depomed](#)
[Eli Lilly Co.](#)
[Europain](#)
[German Research Network on Neuropathic Pain](#)
[Horizon Pharma](#)
[International Association for the Study of Pain](#)
[Jazz Pharmaceuticals](#)
[Johnson & Johnson](#)
[Neuropathy Association](#)
[Olatec Industries LLC](#)
[Osteoarthritis Research Society International](#)
[Outcome Measures in Rheumatology](#)
[Pfizer](#)
[Purdue](#)
[Spinifex](#)
[Teva](#)
[U.S. Food and Drug Administration](#)

Updated: **04/06/2016**